| Gordon T Sakamoto, M D | |
|
1501 Trousdale Dr, 3rd Floor, Burlingame, CA 94010-4506 | |
| (650) 652-8520 | |
| Not Available |
| Full Name | Gordon T Sakamoto |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 21 Years |
| Location | 1501 Trousdale Dr, Burlingame, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417137233 | NPI | - | NPPES |
| A88940 | Other | CA | CA MEDICAL LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | A88940 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Peninsula Medical Center | Burlingame, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sutter Bay Medical Foundation | 4284538778 | 2941 |
News Archive
A team of researchers affiliated with Ludwig Cancer Research and the Karolinska Institutet in Sweden report in the current issue of Nature Methods a dramatically improved technique for analyzing the genes expressed within a single cell - a capability of relevance to everything from basic research to future cancer diagn
A study aimed at overcoming problems with treatments for a common cause of back pain has picked up one of the most prestigious prizes in spinal research.
BioTrends is pleased to announce the publication of the second wave of a syndicated report, LaunchTrends®: ACTEMRA. Actemra (tocilizumab), marketed by Roche-Genentech, is the first IL-6 receptor inhibitor agent approved for rheumatoid arthritis (RA). This report is the second in a three-wave series derived from on-line survey responses from 80 rheumatologists and qualitative interviews with 20 rheumatologists.
The prognosis for nearly three-quarters of elderly patients on intensive chemotherapy for acute myeloid leukemia (AML) is poor, with a median survival of less than six months, according to a study published online today in Blood, the journal of the American Society of Hematology. AML is the most common form of acute leukemia among adults and is a rapidly growing cancer of the bone marrow that requires immediate treatment. The average age at diagnosis is 67, and more than 12,000 people will be diagnosed with AML this year (according to the National Cancer Institute).
A selection of health policy stories from Minnesota, Maryland, Louisiana, Colorado, Nebraska and Florida.
› Verified 8 days ago
| Entity Name | Sutter Bay Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013950807 PECOS PAC ID: 4284538778 Enrollment ID: O20031125000909 |
News Archive
A team of researchers affiliated with Ludwig Cancer Research and the Karolinska Institutet in Sweden report in the current issue of Nature Methods a dramatically improved technique for analyzing the genes expressed within a single cell - a capability of relevance to everything from basic research to future cancer diagn
A study aimed at overcoming problems with treatments for a common cause of back pain has picked up one of the most prestigious prizes in spinal research.
BioTrends is pleased to announce the publication of the second wave of a syndicated report, LaunchTrends®: ACTEMRA. Actemra (tocilizumab), marketed by Roche-Genentech, is the first IL-6 receptor inhibitor agent approved for rheumatoid arthritis (RA). This report is the second in a three-wave series derived from on-line survey responses from 80 rheumatologists and qualitative interviews with 20 rheumatologists.
The prognosis for nearly three-quarters of elderly patients on intensive chemotherapy for acute myeloid leukemia (AML) is poor, with a median survival of less than six months, according to a study published online today in Blood, the journal of the American Society of Hematology. AML is the most common form of acute leukemia among adults and is a rapidly growing cancer of the bone marrow that requires immediate treatment. The average age at diagnosis is 67, and more than 12,000 people will be diagnosed with AML this year (according to the National Cancer Institute).
A selection of health policy stories from Minnesota, Maryland, Louisiana, Colorado, Nebraska and Florida.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gordon T Sakamoto, M D 325 Distel Cir, Los Altos, CA 94022-1408 Ph: (650) 652-8520 | Gordon T Sakamoto, M D 1501 Trousdale Dr, 3rd Floor, Burlingame, CA 94010-4506 Ph: (650) 652-8520 |
News Archive
A team of researchers affiliated with Ludwig Cancer Research and the Karolinska Institutet in Sweden report in the current issue of Nature Methods a dramatically improved technique for analyzing the genes expressed within a single cell - a capability of relevance to everything from basic research to future cancer diagn
A study aimed at overcoming problems with treatments for a common cause of back pain has picked up one of the most prestigious prizes in spinal research.
BioTrends is pleased to announce the publication of the second wave of a syndicated report, LaunchTrends®: ACTEMRA. Actemra (tocilizumab), marketed by Roche-Genentech, is the first IL-6 receptor inhibitor agent approved for rheumatoid arthritis (RA). This report is the second in a three-wave series derived from on-line survey responses from 80 rheumatologists and qualitative interviews with 20 rheumatologists.
The prognosis for nearly three-quarters of elderly patients on intensive chemotherapy for acute myeloid leukemia (AML) is poor, with a median survival of less than six months, according to a study published online today in Blood, the journal of the American Society of Hematology. AML is the most common form of acute leukemia among adults and is a rapidly growing cancer of the bone marrow that requires immediate treatment. The average age at diagnosis is 67, and more than 12,000 people will be diagnosed with AML this year (according to the National Cancer Institute).
A selection of health policy stories from Minnesota, Maryland, Louisiana, Colorado, Nebraska and Florida.
› Verified 8 days ago